Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas
Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas
Active, not recruiting · NCT03071874 · Registry updated 2022-10-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Nerve Tissue, central nervous system cancer, meningioma, neoplasm, nervous system disorder, tumor of meninges, vascular cancer | Active, not recruiting | Phase 2 | 2022-10-18 | NCT03071874 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Massachusetts General Hospital | 758 |
| National Cancer Institute (NCI) | 3015 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana Farber Cancer Institute | Boston | United States | 133 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| Northwestern University | Chicago | United States | 727 |